RELMADA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number
RELMADA THERAPEUTICS, INC. (RLMD) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number of 10.80 million shares as of 2026-03-31, per its 10-Q filed 2026-05-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber · last filed 2026-05-12
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number 10.80M shares.
- 2024-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number 8.89M shares.
- 2024-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number 8.29M shares.
- 2023-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number 7.16M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number |
|---|---|
| 2026-03-31 | 10.80M shares 10-Q · filed 2026-05-12 |
| 2024-09-30 | 8.89M shares 10-Q · filed 2024-11-07 |
| 2024-06-30 | 8.29M shares 10-Q · filed 2024-08-07 |
| 2023-12-31 | 7.16M shares 10-K · filed 2024-03-19 |
| 2023-09-30 | 6.56M shares 10-Q · filed 2023-11-08 |
| 2023-06-30 | 5.60M shares 10-Q · filed 2023-08-08 |
| 2023-03-31 | 4.77M shares 10-Q · filed 2023-05-11 |
| 2022-12-31 | 4.36M shares 10-K · filed 2023-03-23 |
| 2021-12-31 | 2.14M shares 10-K · filed 2022-03-25 |
| 2015-06-30 | 301.50K shares 10-K · filed 2015-09-11 |
| 2014-06-30 | 652.00K shares 10-KT · filed 2014-09-09 |
| 2014-03-31 | 5.89M shares 8-K · filed 2014-05-27 |
| 2013-12-31 | 5.26M shares 8-K · filed 2014-05-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |